Article Information
History
- August 17, 2023.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Guanglei Chen1,2,3,
- Xi Gu1,2,3,
- Xu Zhang1,
- Xiaopeng Yu1,
- Yu Zhang1,4,
- Jinqi Xue1,2,3,
- Ailin Li1,
- Yi Zhao1,
- Guijin He1,
- Meiyue Tang1,
- Fei Xing1,
- Jianqiao Yin1,
- Xiaobo Bian1,
- Ye Han1,
- Shuo Cao1,
- Chao Liu1,2,3,
- Xiaofan Jiang1,2,3,
- Keliang Zhang5,
- Yan Xia6,
- Huajun Li6,
- Nan Niu1,2,3 and
- Caigang Liu1,2,3,*
- 1Department of Oncology, Shengjing Hospital of China Medical University, Shenyang, China
- 2Cancer Stem Cell and Translational Medicine Laboratory, Shengjing Hospital of China Medical University, Shenyang, China
- 3Innovative Cancer Drug Research and Development Engineering Center of Liaoning Province, Shenyang, China
- 4Department of Gastrointestinal Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai, China
- 5Liaoning Center for Drug Evaluation and Inspection, Shenyang, China
- 6Jiangsu Hengrui Pharmaceuticals, Shanghai, China
- ↵*Correspondence
to Caigang Liu, Department of Oncology, Shengjing Hospital of China Medical University, Shenyang 110004, China., E-mail: liucg{at}sj-hospital.org
Posted August 17, 2023.
Efficacy and Safety of neoadjuvant stereotactic body radiotherapy plus adebrelimab and chemotherapy for triple-negative breast cancer: A pilot study
